| 1 | we live by | | | | | | | 6 | 0.44% |
| 2 | 17 words we live | | | | | | | 6 | 0.44% |
| 3 | words we live by | | | | | | | 6 | 0.44% |
| 4 | to see opportunities in | | | | | | | 3 | 0.22% |
| 5 | here to see opportunities | | | | | | | 3 | 0.22% |
| 6 | click here to see | | | | | | | 3 | 0.22% |
| 7 | the science and investment | | | | | | | 2 | 0.15% |
| 8 | reach of gene therapies | | | | | | | 2 | 0.15% |
| 9 | heart of 908 systems | | | | | | | 1 | 0.07% |
| 10 | such as cell cultures | | | | | | | 1 | 0.07% |
| 11 | times smaller than those | | | | | | | 1 | 0.07% |
| 12 | cgmp manufacturing both in | | | | | | | 1 | 0.07% |
| 13 | manufacturing both in vivo | | | | | | | 1 | 0.07% |
| 14 | both in vivo in | | | | | | | 1 | 0.07% |
| 15 | in vivo in human | | | | | | | 1 | 0.07% |
| 16 | vivo in human and | | | | | | | 1 | 0.07% |
| 17 | in human and ex | | | | | | | 1 | 0.07% |
| 18 | human and ex vivo | | | | | | | 1 | 0.07% |
| 19 | external to humans such | | | | | | | 1 | 0.07% |
| 20 | to humans such as | | | | | | | 1 | 0.07% |
| 21 | humans such as cell | | | | | | | 1 | 0.07% |
| 22 | as cell cultures capabilities | | | | | | | 1 | 0.07% |
| 23 | the heart of 908 | | | | | | | 1 | 0.07% |
| 24 | cell cultures capabilities exist | | | | | | | 1 | 0.07% |
| 25 | cultures capabilities exist learn | | | | | | | 1 | 0.07% |
| 26 | molecular traps a thousand | | | | | | | 1 | 0.07% |
| 27 | in cgmp manufacturing both | | | | | | | 1 | 0.07% |
| 28 | are molecular traps a | | | | | | | 1 | 0.07% |
| 29 | systems are molecular traps | | | | | | | 1 | 0.07% |
| 30 | 908 systems are molecular | | | | | | | 1 | 0.07% |
| 31 | capabilities exist learn more | | | | | | | 1 | 0.07% |
| 32 | 908 devices at the | | | | | | | 1 | 0.07% |
| 33 | devices at the heart | | | | | | | 1 | 0.07% |
| 34 | at the heart of | | | | | | | 1 | 0.07% |
| 35 | of 908 systems are | | | | | | | 1 | 0.07% |
| 36 | casdin capital logo missionvalues | | | | | | | 1 | 0.07% |
| 37 | property is coupled with | | | | | | | 1 | 0.07% |
| 38 | capabilities in cgmp manufacturing | | | | | | | 1 | 0.07% |
| 39 | target both rare and | | | | | | | 1 | 0.07% |
| 40 | have engineered more than | | | | | | | 1 | 0.07% |